Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 2;12(9):2017-2019.
doi: 10.1158/2159-8290.CD-22-0702.

Why ARNT Prostate Tumors Responding to Enzalutamide?

Affiliations
Editorial

Why ARNT Prostate Tumors Responding to Enzalutamide?

Meng Zhang et al. Cancer Discov. .

Abstract

Prostate tumors can develop resistance to androgen receptor (AR)-targeted therapies through treatment-induced changes in transcription factor activity that promote transcriptional and morphologic features of a neuroendocrine lineage. This study identifies an unexpected role for the circadian protein ARNTL in resistance to enzalutamide, a second-generation AR-targeted therapy. See related article by Linder et al., p. 2074 (4).

Trial registration: ClinicalTrials.gov NCT03297385.

PubMed Disclaimer

Comment on

  • Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
    Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, Alkemade M, Bekers EM, Severson TM, Sanders J, Huang CF, Morova T, Altintas UB, Hoekman L, Kim Y, Baca SC, Sjöström M, Zaalberg A, Hintzen DC, de Jong J, Kluin RJC, de Rink I, Giambartolomei C, Seo JH, Pasaniuc B, Altelaar M, Medema RH, Feng FY, Zoubeidi A, Freedman ML, Wessels LFA, Butler LM, Lack NA, van der Poel H, Bergman AM, Zwart W. Linder S, et al. Cancer Discov. 2022 Sep 2;12(9):2074-2097. doi: 10.1158/2159-8290.CD-21-0576. Cancer Discov. 2022. PMID: 35754340 Free PMC article.

MeSH terms

Associated data

LinkOut - more resources